The price of Asensus Surgical Inc (AMEX: ASXC) closed at $0.30 in the last session, down -1.17% from day before closing price of $0.30. In other words, the price has decreased by -$0.0035 from its previous closing price. On the day, 695558 shares were traded.
Ratios:
We take a closer look at ASXC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.24 and its Current Ratio is at 3.79. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.10.
On September 08, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $1.50.
On May 26, 2021, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $4.H.C. Wainwright initiated its Buy rating on May 26, 2021, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 14 ’23 when Starling William N JR bought 18,134 shares for $0.28 per share. The transaction valued at 5,078 led to the insider holds 39,134 shares of the business.
Starling William N JR sold 18,134 shares of ASXC for $5,078 on Dec 14 ’23. The Director now owns 0 shares after completing the transaction at $0.28 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASXC now has a Market Capitalization of 79.47M and an Enterprise Value of 51.88M. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.97 while its Price-to-Book (P/B) ratio in mrq is 1.66. Its current Enterprise Value per Revenue stands at 9.25 whereas that against EBITDA is -0.69.
Stock Price History:
Over the past 52 weeks, ASXC has reached a high of $0.86, while it has fallen to a 52-week low of $0.20. The 50-Day Moving Average of the stock is 0.2996, while the 200-Day Moving Average is calculated to be 0.3365.
Shares Statistics:
According to the various share statistics, ASXC traded on average about 1.22M shares per day over the past 3-months and 1.03M shares per day over the past 10 days. A total of 264.32M shares are outstanding, with a floating share count of 259.00M. Insiders hold about 2.01% of the company’s shares, while institutions hold 9.96% stake in the company. Shares short for ASXC as of Feb 15, 2024 were 17.05M with a Short Ratio of 13.93, compared to 19.41M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.43% and a Short% of Float of 6.55%.
Earnings Estimates
The company has 1 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.08, while EPS last year was -$0.08. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.33 and -$0.33 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is -$0.19, with 1 analysts recommending between -$0.19 and -$0.19.
Revenue Estimates
According to 1 analysts, the current quarter’s revenue is expected to be $5.3M. It ranges from a high estimate of $5.3M to a low estimate of $5.3M. As of the current estimate, Asensus Surgical Inc’s year-ago sales were $2.46M, an estimated increase of 115.10% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $1.5M, an increase of 53.70% less than the figure of $115.10% in the same quarter last year. There is a high estimate of $1.5M for the next quarter, whereas the lowest estimate is $1.5M.
A total of 1 analysts have provided revenue estimates for ASXC’s current fiscal year. The highest revenue estimate was $8.4M, while the lowest revenue estimate was $8.4M, resulting in an average revenue estimate of $8.4M. In the same quarter a year ago, actual revenue was $7.09M, up 18.50% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $11.8M in the next fiscal year. The high estimate is $11.8M and the low estimate is $11.8M. The average revenue growth estimate for next year is up 40.50% from the average revenue estimate for this year.
